Kidney Cancer Journal

Kidney Cancer Journal

Articles by Kidney Cancer Journal

Active Surveillance for von Hippel-Lindau-Related Renal Tumors using Size-Based Risk Stratification: Longterm Results

Active Surveillance for von Hippel-Lindau-Related Renal Tumors using Size-Based Risk Stratification: Longterm Results Abstract Renal cell carcinoma (RCC) develops in 25-60% of patients von Hippel-Lindau (VHL), which is characterized by germline mutations in the VHL gene. Our institution practice has been to perform active surveillance for renal lesions less than 3 cm and surgical resection for lesions greater than 3 cm, based on early observations of low metastatic potential of small lesions. However, patients who are referred with larger tumors or who are lost to follow-up may not be managed exclusively by this guideline. We sought to evaluate the oncologic efficacy...

Read More

Variations in treatment patterns for metastatic renal cell carcinoma (mRCC) between developing and developed countries

Variations in treatment patterns for metastatic renal cell carcinoma (mRCC) between developing and developed countries Abstract We have previously reported patterns of care for mRCC using a large US-based retrospective chart review encompassing 1,173 patients (pts) (Pal et al Int J Urol 2017). We hypothesize that treatment patterns in developing and developed countries will have marked variation. From Jan 2013 to Dec 2016, pts with mRCC receiving treatment at private or public hospitals in Brazil had receipt of systemic therapy (tx) recorded in a prospective database. Basic clinical and demographic criteria were available, as well as information to ascertain Heng risk....

Read More

Validation of the Preoperative Nomogram Predicting 12-Year Probability of Metastatic Renal Cancer

Validation of the Preoperative Nomogram Predicting 12-Year Probability of Metastatic Renal Cancer Abstract We previously published a predictive model to determine the preoperative risk of metastatic recurrence in localized renal cell carcinoma. We sought to validate this initial nomogram and interrogate the additive value of somatic mutations in a subcohort with available genomic data. We conducted a retrospective review of all non metastatic patients at a single tertiary referral center from 2004–2011 who underwent a surgical extirpation for a renal mass (n=2391). Mutations in VHL, PBRM1, SETD2, BAP1, KDM5C for those patients who had genomic analysis by previously described...

Read More

Updated Results From a Phase I Study of Nivolumab in Combination With Sunitinib or Pazopanib in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Updated Results From a Phase I Study of Nivolumab in Combination With Sunitinib or Pazopanib in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study Abstract Preliminary results from the phase I, open-label, parallel-cohort, dose-escalation CheckMate 016 study combining nivolumab, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, with the tyrosine kinase inhibitors (TKIs) sunitinib or pazopanib for patients with metastatic renal cell carcinoma (mRCC), have shown encouraging clinical activity, albeit with substantial toxicity (Amin et al. ESMO 2014). Here we present updated safety and efficacy results with extended follow-up. Patients with mRCC received nivolumab plus sunitinib...

Read More

Updated Results From a Phase I Study of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Updated Results From a Phase I Study of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study Abstract Combination immune checkpoint inhibitor regimens have demonstrated enhanced antitumor activity compared with monotherapy in multiple tumor types. Two combination regimens with low or high doses of nivolumab and ipilimumab (nivolumab 3 mg/kg + ipilimumab 1 mg/kg [N3I1 arm], nivolumab 1 mg/kg + ipilimumab 3 mg/kg [N1I3 arm]) recently demonstrated efficacy and safety in the open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study in patients with metastatic renal cell carcinoma (mRCC) (Hammers et al. JCO 2017). Here...

Read More

Join the GRU Community

- Why Join? -